Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Cytosine
  • Dioxolanes
  • Neoplasms
  • Salvage Therapy

abstract

  • Recommended doses for phase II studies of troxacitabine as a 30-minute infusion daily for 5 days every 4 weeks are 1.5 and 1.2 mg/m(2)/d for MP and HP patients, respectively. Broad disease-directed evaluations of troxacitabine on this schedule and possibly less frequent schedules are warranted.

publication date

  • January 2002

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.20.1.96

PubMed ID

  • 11773159

Additional Document Info

start page

  • 96

end page

  • 109

volume

  • 20

number

  • 1